# Pembrolizumab (+) berahyaluronidase alfa PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa

> The next catalyst for pembrolizumab (+) berahyaluronidase alfa, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pembrolizumab (+) berahyaluronidase alfa |
| Codes | MK-3475A |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Squamous Cell Carcinoma](https://sec-api.dev/indications/squamous-cell-carcinoma), Classical Hodgkin Lymphoma Recurrent |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06041802 (A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06041802

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06041802 (A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06041802

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06504394 (A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06504394

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06504394 (A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06504394

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pembrolizumab (+) berahyaluronidase alfa PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa

```bibtex
@misc{secapidev_pdufa_pembrolizumab_berahyaluronidase_alfa_20261116,
  title        = {Pembrolizumab (+) berahyaluronidase alfa PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pembrolizumab_berahyaluronidase_alfa_20261116","title":"Pembrolizumab (+) berahyaluronidase alfa PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
